Platelet-derived chemokines in vascular biology

Thrombosis and Haemostasis

Volumn 97, Issue 5, 2007, Pages 704-713

  von Hundelshausen, Philipp ^a   Petersen, Frank ^b   Brandt, Ernst ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Angiogenesis and inhibitors; Atherosclerosis; Chemokines; Platelet immunology

Indexed keywords

BETA THROMBOGLOBULIN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL4L1 CHEMOKINE; CXCL7 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE FACTOR 4; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; BLEEDING; CELL ADHESION; ENZYME REGULATION; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULARIZATION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; CHEMOKINES; HUMANS; MICE; MODELS, IMMUNOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET ACTIVATION; PLATELET FACTOR 4; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 34249062545     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-01-0066     Document Type: Review

References (144)

1. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
2. Thaulow E, Erikssen J, Sandvik L, et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
3. Baltus T, von Hundelshausen P, Mause SF, et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 8: 435-441.
4. Koenen RR, Weber C. Fine-tuning leukocyte responses: towards a chemokine "interactome". Trends Immunol 2006; 27: 268-273.
5. Schiemann F, Grimm TA, Hoch J, et al. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 2006; 107: 2234-2242.
6. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med 2001; 11: 403-417.
7. Brandt E, Ludwig A, Petersen F, et al. Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000; 177: 204-216.
8. Struyf S, Burdick MD, Proost P, et al. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004; 95: 855-857.
9. Klinger MH. Platelets and inflammation. Anat Embryol (Berl) 1997; 196: 1-11.
10. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-350.
11. Massberg S, Konrad I, Schurzinger K, et al. Platelets secrete stromal ccll-derived factor 1 {alpha} and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-33.
12. Schober A, Zernecke A. Chemokines in vascular remodelling. Thromb Haemost 2007; 97: 730-737.
13. Klinger MH, Wilhelm D, Bubel S, et al. Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 1995; 107: 541-546.
14. Kameyoshi Y, Dorschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176: 587-592.
15. Fujisawa T, Fujisawa R, Kato Y, et al. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110: 139-146.
16. Brandt E, Petersen F, Ludwig A, et al. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000; 67: 471-478.
17. Moore S, Pepper DS, Cash JD. The isolation and characterisation of a platelet-specific beta-globulin (beta-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochim Biophys Acta 1975; 379: 360-369.
18. Begg GS, Pepper DS, Chesterman CN, et al. Complete covalent structure of human beta-thromboglobulin. Biochemistry 1978; 17: 1739-1744.
19. Majumdar S, Gonder D, Koutsis B, et al. Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4. J Biol Chem 1991; 266: 5785-5789.
20. Zhang C, Gadue P, Scott E, et al. Activation of the megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1. J Biol Chem 1997; 272: 26236-26246.
21. Holt JC, Rabellino EM, Gewirtz AM, et al. Occurrence of platelet basic protein, a precursor of low affinity platelet factor 4 and beta-thromboglobulin, in human platelets and megakaryocytes. Exp Hematol 1988; 16: 302-306.
22. Resmi KR, Krishnan LK. Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation. Thromb Res 2002; 106: 229-236.
23. Brandt E, Van Damme J, Flad HD. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokine 1991; 3: 311-321.
24. Walz A, Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990; 171: 449-454.
25. Car BD, Baggiolini M, Walz A. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem J 1991; 275: 581-584.
26. Harter L, Petersen F, Flad HD, et al. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2. J Immunol 1994; 153: 5698-5708.
27. Walz A, Dewald B, von Tscharner V, et al. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 1989; 170: 1745-1750.
28. Castor CW, Walz DA, Johnson PH, et al. Connective tissue activation. XXXIV. Effects of proteolytic processing on the biologic activities of CTAP-III. J Lab Clin Med 1990; 116: 516-526.
29. Tai PK, Liao JF, Hossler PA, et al. Regulation of glucose transporters by connective tissue activating peptide-III isoforms. J Biol Chem 1992; 267: 19579-19586.
30. Iida N, Haisa M, Igarashi A, et al. Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. Faseb J 1996; 10: 1336-1345.
31. Pillai MM, Iwata M, Awaya N, et al. Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 2006; 107: 3520-3526.
32. Han ZC, Bellucci S, Walz A, et al. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Int J Cell Cloning 1990; 8: 253-259.
33. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood 1995; 86: 2559-2567.
34. Oda M, Kurasawa Y, Todokoro K, et al. Thrombopoietin-induced CXC chemokines, NAP-2 and PF4, suppress polyploidization and proplatelet formation during megakaryocyte maturation. Genes Cells 2003; 8: 9-15.
35. Abgrall JF, Berthou C, Cauvin JM, et al. Spontaneous in vitro megakaryocyte colony formation in primary thrombocythemia: relation to platelet factor 4 plasma level and beta-thromboglobulin/platelet factor 4 ratio. Acta Haematol 1992; 87: 118-121.
36. Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005; 105: 464-473.
37. Clark-Lewis I, Dewald B, Loetscher M, et al. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem 1994; 269: 16075-16081.
38. Yan Z, Zhang J, Holt JC, et al. Structural requirements of platelet chemokines for neutrophil activation. Blood 1994; 84: 2329-2339.
39. Malkowski MG, Lazar JB, Johnson PH, et al. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol 1997; 266: 367-380.
40. Petersen F, Flad HD, Brandt E. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects. J Immunol 1994; 152: 2467-2478.
41. Ehlert JE, Ludwig A, Grimm TA, et al. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood 2000; 96: 2965-2972.
42. Schenk BI, Petersen F, Flad HD, et al. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol 2002; 169: 2602-2610.
43. Schwartzkopff F, Brandt E, Petersen F, et al. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor. J Interferon Cytokine Res 2002; 22: 257-267.
44. Loetscher P, Seitz M, Clark-Lewis I, et al. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett 1994; 341: 187-192.
45. Ahuja SK, Murphy PM. The CXC chemokines growth-regulatcd oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996; 271: 20545-20550.
46. Ludwig A, Petersen F, Zahn S, et al. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood 1997; 90: 4588-4597.
47. Ehlert JE, Gerdes J, Flad HD, et al. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions. J Immunol 1998; 161: 4975-4982.
48. Ehlert JE, Petersen F, Kubbutat MH, et al. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants. J Biol Chem 1995; 270: 6338-6344.
49. Krijgsveld J, Zaat SA, Meeldijk J, et al. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374-20381.
50. Dankert J, Krijgsveld J, van Der Werff J, et al. Platelet microbicidal activity is an important defense factor against viridans streptococcal endocarditis. J Infect Dis 2001; 184: 597-605.
51. Schnitzel W, Monschein U, Besemer J. Monomerdimer equilibria of interleukin-8 and neutrophil-activating peptide 2. Evidence for IL-8 binding as a dimer and oligomer to IL-8 receptor B. J Leukoc Biol 1994; 55: 763-770.
52. Deuel TF, Keim PS, Farmer M, et al. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977; 74: 2256-2258.
53. Deuel TF, Senior RM, Chang D, et al. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981; 78: 4584-4587.
54. Bebawy ST, Gorka J, Hyers TM, et al. In vitro effects of platelet factor 4 on normal human neutrophil functions. J Leukoc Biol 1986; 39: 423-434.
55. Clark-Lewis I, Dewald B, Geiser T, et al. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA 1993; 90: 3574-3577.
56. Petersen F, Ludwig A, Flad HD, et al. TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol 1996; 156: 1954-1962.
57. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169: 770-777.
58. Pervushina O, Scheuerer B, Reiling N, et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 2004; 173: 2060-2067.
59. Brandt E, Ernst M, Loppnow H, et al. Characterization of a platelet derived factor modulating phagocyte functions and cooperating with interleukin 1. Lymphokine Res 1989; 8: 281-287.
60. Walz A, Baggiolini M. A novel cleavage product of beta-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun 1989; 159: 969-975.
61. Schaffner A, Rhyn P, Schoedon G, et al. Regulated expression of platelet factor 4 in human monocytes - role of PARs as a quantitatively important monocyte activation pathway. J Leukoc Biol 2005; 78: 202-209.
62. Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007; epub ahead of print.
63. Files JC, Malpass TW, Yee EK, et al. Studies of human plate alpha-granule release in vivo. Blood 1981; 58: 607-618.
64. Levine SP, Krentz LS. Development of a radio-immunoassay for human platelet factor 4. Thromb Res 1977; 11: 673-686.
65. Green CJ, Charles RS, Edwards BF, et al. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol 1989; 9: 1445-1451.
66. Eisman R, Surrey S, Ramachandran B, et al. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990; 76: 336-344.
67. Petersen F, Bock L, Flad HD, et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998; 161: 4347-4355.
68. Kasper B, Brandt E, Ernst M, et al. Neutrophil adhesion to endothelial cells induced by platelet factor 4 requires sequential activation of Ras, Syk, and JNK MAP kinases. Blood 2006; 107: 1768-1775.
69. Kasper B, Brandt E, Bulfone-Paus S, et al. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases while PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. Blood 2004; 103: 1602-1610.
70. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-1549.
71. Han ZC, Lu M, Li J, et al. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 1997; 89: 2328-2335.
72. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine, binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995; 182: 219-231.
73. Watson JB, Getzler SB, Mosher DF. Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 1994; 94: 261-268.
74. Gengrinovitch S, Greenberg SM, Cohen T, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995; 270: 15059-15065.
75. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-79.
76. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3: 437-442.
77. Perollet C, Han ZC, Savona C, et al. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-3299.
78. Sulpice E, Contreres JO, Lacour J, et al. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004; 271: 3310-3318.
79. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
80. Liu CY, Battaglia M, Lee SH, et al. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. J Immunol 2005; 174: 2680-2686.
81. Vaddi K, Newton RC. Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the intercrine-beta family. J Leukoc Biol 1994; 55: 756-762.
82. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
83. Fricke I, Mitchell D, Petersen F, et al. Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells. Faseb 12004; 18: 1588-1590.
84. Petersen F, Bock L, Flad HD, et al. Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood 1999; 94: 4020-4028.
85. Marti F, Bertran E, Llucia M, et al. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol 2002; 72: 590-597.
86. Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immumol 2005; 116: 1372-1379.
87. Han ZC, Sensebe L, Abgrall JE et al. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 1990; 75: 1234-1239.
88. Hayashi N, Chihara J, Kobayashi Y, et al. Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int Arch Allergy Immunol 1994; 104 Suppl 1: 57-59.
89. Schall TJ, Jongstra J, Dyer BJ, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988; 141: 1018-1025.
90. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671.
91. Rot A, Krieger M, Brunner T, et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992; 176: 1489-1491.
92. Nesmelova IV, Sham Y, Dudek AZ, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005; 280: 4948-4958.
93. Skelton NJ, Aspiras F, Ogez J, et al. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry 1995; 34: 5329-5342.
94. Wang JM, McVicar DW, Oppenheim JJ, et at. Identification of RANTES receptors on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines. J Exp Med 1993; 177: 699-705.
95. Van Riper G, Siciliano S, Fischer PA, et al, Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1. J Exp Med 1991; 177: 851-856.
96. Gao JL, Kuhns DB, Tiffany HL, et al. Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med 1993; 177: 1421-1427.
97. Neote K, DiGregorio D, Mak JY, et al. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1903; 72: 415-425.
98. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
99. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 1995; 270: 16491-16494.
100. Power CA, Meyer A, Nemeth K, et al. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J Biol Chem 1995; 270: 19495-19500.
101. Raport CJ, Gosling J, Schweickart VL, et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996; 271: 17161-17166.
102. Combadiere C, Ahuja SK, Tiffany HL, et al, Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol 1996; 60: 147-152.
103. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815,
104. Lim JK, Glass WG, McDermott DH, et al. CCR5: no longer a "good for nothing" gene - chemokine control of West Nile virus infection. Trends Immunol 2006; 27: 308-312.
105. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
106. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
107. Bacon KB, Szabo MC, Yssel H, et al. RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells. J Exp Med 1996; 184: 873-882.
108. Gong JH, Uguccioni M, Dewald B, et al. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 1996; 271: 10521-10527.
109. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186: 1865-1872.
110. Weber C, Weber KS, Klier C, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/ CD45RO(+) T cells. Blood 2001; 97: 1144-1146.
111. Nieto M, Frade JM, Sancho D, et al. Polarization of chemokine receptors to the leading edge during lymphocyte chemotaxis. J Exp Med 1997; 186: 153-158.
112. Chuluyan HE, Schall TJ, Yoshimura T, et al. IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1 alpha, RANTES, and PAF but inhibits migration to MCP-1: a regulatory role for endothelium-derived MCP- 1. J Leukoc Biol 1995; 58: 71-79.
113. Szabo MC, Butcher EC, McIntyre BW, et al. RANTES stimulation of T lymphocyte adhesion and activation: role for LFA-1 and ICAM-3. Eur J Immunol 1997; 27: 1061-1068.
114. Bacon KB, Premack BA, Gardner P, et al. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995; 269: 1727-1730.
115. Appay V, Dunbar PR, Cerundolo V, et al. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol 2000; 12: 1173-1182.
116. Gilat D, Hershkoviz R, Mekori YA, et al. Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol 1994; 153: 4899-4906.
117. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
118. Zhang X, Chen L, Bancroft DP, et al. Crystal structure of recombinant human platelet factor 4. Biochemistry 1994; 33: 8361-8366.
119. Martin L, Blanpain C, Garnier P, et al. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001; 40: 6303-6318.
120. Proudfoot AE, Fritchley S, Borlat F, et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001; 276: 10620-10626.
121. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1890.
122. Czaplewski LG, McKeating J, Craven CJ, et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem 1999; 274: 16077-16084.
123. Baltus T, Weber KS, Johnson Z, et al. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 2003; 102: 1985-1988.
124. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994; 4: 394-400.
125. Hoogewerf AJ, Kuschert GS, Proudfoot AE, et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997; 36: 13570-13578.
126. Ali S, Palmer AC, Banejee B, et al. Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J Biol Chem 2000; 275: 11721-11727.
127. Huo Y, Schober A, Forlow B, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
128. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
129. Mause SF, von Hundelshausen P, Zernecke A, et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512-1518.
130. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
131. Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-61.
132. Simeoni E, Winkelmann BR, Hoffmann MM, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004; 25: 1438-1446.
133. Rothenbacher D, Muller-Scholze S, Herder C, et al. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194-199.
134. Muhlhauser I, Schernthaner G, Silberbauer Y, et al. Platelet proteins (beta-TG and PF4) in atherosclerosis and related diseases. Artery 1980; 8: 73-79.
135. Levine SP, Lindenfeld J, Ellis JB, et al. Increased plasma concentrations of platelet factor 4 in coronary artery disease: a measure of in vivo platelet activation and secretion. Circulation 1981; 64: 626-632.
136. O'Brien JF, Etherington MD, Pashley M. Intraplatelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis. Thromb Haemost 1984; 51: 354-357.
137. Pitsilos S, Hunt J, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90: 1112-1120.
138. Sachais BS, Kuo A, Nassar T, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613-3622.
139. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187-6193.
140. Smith C, Damas JK, Otterdal K, et al. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 2006; 48: 1591-1599.
141. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenecity.. Thromb Haemost 2007; 97: 722-729.
142. Rhee JS, Black M, Schubert U, et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402.
143. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-235.
144. Hristov M, Zernecke A, Bidzhekov K, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; epub ahead of print.